Takeda Pharmaceutical (TAK) Gets GAMMAGARD LIQUID ERC Approved by FDA

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the 13 Best Japanese Stocks to Buy According to Hedge Funds. On June 30, Takeda Pharmaceutical Company Limited (NYSE:TAK) announced that it has received US Food and Drug Administration (FDA) approval for AMMAGARD LIQUID ERC with less than or equal to 2 micrograms per milliliter in a 10% solution.

AMMAGARD LIQUID ERC is the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content that is approved for use as a replacement therapy for people aged two years and older who have primary immunodeficiency (PI).

As a ready-to-use liquid, GAMMAGARD LIQUID ERC can be administered intravenously or subcutaneously. This can help make treatment easier for patients and healthcare providers by removing the need for reconstitution.

Takeda Pharmaceutical Company Limited (NYSE:TAK) expects the commercialization of GAMMAGARD LIQUID ERC to start in the US in 2026. The company expects to launch it in the European Union in 2027, where it has already been approved by the European Medicines Agency (EMA) as DEQSIGA.

Takeda Pharmaceutical Company Limited (NYSE:TAK) is a Japanese multinational biopharmaceutical company that discovers and develops a range of treatments. The company’s core therapeutic and business areas include gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.

While we acknowledge the potential of TAK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.